Skip to main content

Table 2 Degree of protective efficacy of the vaccines as evaluated by the isolation rate of Brucella from the spleens of guinea pigs challenged with the virulent strain B. abortus 544

From: Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection

Vaccine Route of administration Log10CFU/spleen (mean ± SE) Log10protection *Value (P)
Monovalent Flu-NS1-124-Omp 16 (H5 + H1) i.n. 2.0 ± 0.52 2.54 <0.01
c. 0.76 ± 0.44 3.78 <0.001
s.c. 1.26 ± 0.52 3.28 <0.005
Monovalent Flu-NS1-124-L7L12 (H5 + H1) i.n. 1.22 ± 0.50 3.32 <0.001
c. 2.4 ± 0.25 2.14 <0.005
s.c. 1.46 ± 0.39 3.08 <0.001
Bivalent vaccine formulation Flu-NS1-124-Omp 16 + Flu-NS1-124-L7L12 (H5 + H1) i.n. 1.28 ± 0.52 3.26 <0.005
c. 0.64 ± 0.40 3.90 <0.001
s.c. 1.68 ± 0.51 2.86 <0.005
B. abortus 19 s.c. 0.42 ± 0.26 4.12 <0.001
Control (PBS) s.c. 4.54 ± 0.43 0.00  
  1. i.n. – intranasally, c. – conjunctivally, s.c. – subcutaneously; *compared with control group. Statistical analysis was performed using a one way ANOVA followed by Tukey’s multiple comparisons test.